Type 2 diabetes is linked to impaired pulmonary function

  • Díez-Manglano J & al.
  • ERJ Open Res
  • 01/01/2021

  • Miriam Tucker
  • Clinical Essentials
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • Type 2 diabetes (T2D) is associated with pulmonary function impairment, independent of sex, smoking status, or worldwide location.

Why this matters

  • Pulmonary function test (PFT) impairment has not been well-studied in people with T2D.

Study design

  • A meta-analysis including 66 studies of 11,134 individuals with T2D and 48,377 control participants without T2D.
  • Funding: None.

Key results

  • Pooled mean differences were as follows:
    • Predicted percentage of FEV1 (41 studies): −7.15 (P<.0001>
    • Predicted percentage of FVC (35 studies): −9.21 (P<.0001>
    • FEV1/FVC ratio (45 studies): −0.27 (P<.69>
    • Forced expiratory flow at 25%-75% of total lung capacity (13 studies): −9.89 (P<.0001>
    • Predicted percentage of peak expiratory flow (15 studies): −9.79 (P<.0001>
  • No differences by sex in 15 studies (P>.25 for all measures).
  • For tobacco use (14 studies included smokers+nonsmokers; 43 nonsmokers only; 9 no smoking data): reductions in lung function measures were greater in studies of nonsmokers than in those that included both (P<.001>
  • Abnormal PFT results observed in those with T2D in all continents.

Limitations

  • Discrepancies in study selection and quality assessment resolved by consensus.
  • Heterogeneity between studies.
  • Only half of the studies included ≥50 with T2D.
  • Most studies did not report results by sex.